Challenging the Treatment of Respiratory Viruses
We are a pioneering biotech company committed to the discovery of new antiviral treatments.
![](https://trippbio.com/wp-content/uploads/2022/07/masks.jpg)
![](https://trippbio.com/wp-content/uploads/2022/07/lab.jpg)
Developing Products with Lower Risk &
Higher Efficacy
As a company, TrippBio is dedicated to enhancing the healthcare treatment industry and changing lives across the globe. Our goal is to bring life-saving treatments to patients worldwide.
Our current product, PanCytoVir™, aims to:
- Lessen Disease Severity
- Block Virus Replication
- Reduce Hyper-Inflammation
Advanced Phases of Testing for Innovative PanCytoVir™ Drug
Pancytovir is currently in clinical testing. It has shown great potential and with its unique mechanism of action could be a key therapeutic drug to help millions.
Current Clinical Trial
TrippBio is currently conducting a randomized, single-center, single-blind, placebo controlled, study to evaluate efficacy of PanCytoVir™ 500 mg twice daily and 1000 mg twice daily for the treatment of non-hospitalized patients with COVID-19 infection (NCT05442983).
![](https://trippbio.com/wp-content/uploads/2022/07/virus3-1024x768.jpg)
Treatment for Emerging Respiratory Viruses
TrippBio focuses on developing innovative applications of existing drugs with low risk and high efficacy to treat viral pathogens like influenza, RSV, and COVID-19.